Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience

OBJECTIVES. Trastuzumab (H) and pertuzumab (P) with standard chemotherapy is approved for use in the neoadjuvant setting for human epidermal growth receptor 2 ‐positive patients. A retrospective analysis was performed of patients treated with dose‐dense (dd) doxorubicin and cyclophosphamide (AC) fol...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncologist
Main Authors: Singh, Jasmeet C., Mamtani, Anita, Barrio, Andrea, Morrow, Monica, Sugarman, Steven, Jones, Lee W., Yu, Anthony F., Argolo, Daniel, Smyth, Lilian M., Modi, Shanu, Schweber, Sarah, Boafo, Camilla, Patil, Sujata, Norton, Larry, Baselga, Jose, Hudis, Clifford A., Dang, Chau
格式: Artigo
語言:Inglês
出版: AlphaMed Press 2017
主題:
Breast Cancer
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330708/
https://ncbi.nlm.nih.gov/pubmed/28167568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0268
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍